Use of Zebrafish Embryo Assay to Evaluate Toxicity and Safety of Bioreactor-Grown Exopolysaccharides and Endopolysaccharides from European *Ganoderma applanatum* Mycelium for Future Aquaculture Applications

Wan Abd Al Qadr Imad Wan-Mohtar 1,2,3, Zul Ilham 2,4, Adi Ainurzaman Jamaludin 4 and Neil Rowan 3,5,*

Abstract: Natural mycelial exopolysaccharide (EPS) and endopolysaccharide (ENS) extracted from bioreactor-cultivated European *Ganoderma applanatum* mushrooms are of potential high commercial value for both food and adjacent biopharmaceutical industries. In order to evaluate their potential toxicity for aquaculture application, both EPS (0.01–10 mg/mL) and ENS (0.01–10 mg/mL) extracts were tested for Zebrafish Embryo Toxicity (ZFET); early development effects on Zebrafish Embryos (ZE) were also analyzed between 24 and 120 h post-fertilization (HPF). Both EPS and ENS are considered non-toxic with LC50 of 1.41 mg/mL and 0.87 mg/mL respectively. Both EPS and ENS did not delay hatching and teratogenic defect towards ZE with <1.0 mg/mL, respectively. No significant changes in the ZE heart rate were detected following treatment with the two compounds tested (EPS: 0.01–10 mg/mL: 176.44 ± 0.77 beats/min and ENS: 0.01–10 mg/mL: 148.44 ± 17.75 beats/min) compared to normal ZE (120–180 beats/min). These initial findings support future pre-clinical trials in adult fish models with view to safely using EPS and ENS as potential feed supplements for supplements for development of the aquaculture industry.

Keywords: *Ganoderma applanatum*; exopolysaccharide; endopolysaccharide; zebrafish; toxicology

1. Introduction

Over the past two decades, medicinal mushroom exopolysaccharides (EPS) and endopolysaccharide (ENS) have been increasingly exploited for human benefits including clinical trials [1], neurological protection [2], potent in vitro biological activities [3], chicken patty [4], anti-oral cancer [5], and breast cancer models [6]; however, there is still limited development as yet on their commercial use by the aquaculture industry. Development and exploitation of medicinal mushroom products has significant potential to improve farmed fish health, where appropriate innovation in fish feed and formulation potentially offers safe, affordable and future intensive sustainability needs [7–9]. Recent evidence suggests the use of bioreactor-grown medicinal mushroom *Ganoderma* sp. extracts in aquaculture-like areas including fish-feed [10], fish toxicity [11], and have passed potential clinical application [12]. These potential applications are largely attributed to its bioactive EPS-ENS components with immuno-stimulatory properties, which can be scaled efficiently and repeatedly for commercial use by deploying a specifically-tailored mushroom bioreactor system [13,14].
Currently, there is an innovation gap in terms of specific use and development of fungal biotechnology for meeting emerging needs in the aquaculture industry globally. However, there are some examples of specific mushroom usage including Shiitake fruiting body for fingerlings of Carps [15] and Rainbow trout feed [16]; thus, use of Ganoderma-derived EPS-ENS that comprise beta-glucans warrants further investigation and testing. Mushroom scientists have previously reported that *G. applanatum* EPS-ENS demonstrated promise as novel disease mitigation therapeutic [17–19], suggesting potential for use as disease prevention counter-measures for adjacent aquaculture industry in the form of prebiotics [20].

The creative idea of using extracts from naturally-occurring algae to address key challenges and opportunities in fish health has been exemplified by Marino et al., [21] who studied use of algal extracts as potential alternatives to that of antibiotics for farming sea bass and gilthead sea bream. Marino et al., [21] highlighted increased interest in the use of natural-alternatives materials to that of frontline antibiotics and biocides, particularly where there is a trend towards producing farmed high-value fish with organic status. Cascio et al., [22] reported on the potential “game-changer” use of a microalgae (Spirulina) targeting beneficial effects in the gastrointestinal tract of Zebras; this has implications for potentially stimulating the breeding of animals. Such studies show the importance of Zebrasfish (*Danio rerio*) assay due to the ability of Zebrasfish stomach system to recognize small extracts such as mRNA and immune-priming genes. The use of beta-glucans-derived from medicinal mushrooms, yeast, algae, seaweed and so forth is of increasing interest as these bio-based therapeutics have shown potential for immune-priming of fish for disease mitigation and for added food security. However, the vast majority of studies to date have focused on extraction of bioactives from raw materials, but not from bioreactor grown systems that are important for larger pilot scale and commercial deployment. It is therefore necessary to test and verify the toxicity status of EPS-ENS polysaccharide extract prior to pilot and commercial use; such as, the use of a zebrasfish larvae model to evaluate these bioactive substances as part of a fish feed formulation study [23,24]. For example, use of antibacterial polysaccharides from *Undaria pinnatifida* (macroalgae) was reported by Rizzo et al., [25] for the treatment of prominent aquaculture disease *Vibrio harveyi* causes death of marine fish [26] due to vasculitis, gastro-enteritis and eye lesions.

Our study used the ZFET strategy as it was previously reported to be a fast, affordable and sensitive approach [11]; it also offers greater flexibility in terms of using multiple sample insertions to evaluate toxicological effects due to early stages of embryonic development [11] and for continuity in terms of relevance to the gastrointestinal anatomy in small intestine mammals [22]. This study reports on the use of ZFET assay for testing European *G. applanatum* extracts using seven different EPS-ENS concentrations that specifically addresses LC50, embryonic hatching delays, teratogenic defect, and heart rate response with clear microscopic images.

2. Results

2.1. Effects of EPS and ENS on the Survival Rate of Zebrafish Embryos

In the ZFET assay, the survival rate of the embryos of the zebrasfish in the range of 0 to 120 h old at the cell culture concentration of 0.01 to 10 mg/mL was analyzed. Based on standard, the normal hatching for zebrasfish embryos is median of 48 to 72 h of post-fertilization (HPF), thus the survival rate of the embryos (prior hatch) and larva (post hatch) treated with EPS-ENS extract was determined for maximum of five days (120 h). In Figure 1, we observe that 100% of untreated embryos survived for up to 120 HPF. However, among pretreating cells with EPS-ENS doses of 0.01 to 1 mg/mL, the survival rate was 88% at 72 HPF. The survival rate dropped from 88% at 72 HPF to 0% for all cells pretreated at the highest EPS-ENS concentrations (5–10 mg/mL). No embryos at >72 HPF managed to survive and developed at EPS concentration >5 mg/mL (Figure 1a). In the meantime, Figure 1b, on low concentrations (0.5–1 mg/mL) of ENS extract, an average drop in survival rate was relatively small (85%), while at higher concentrations (5–10 mg/mL), a lower
survival rate (<30%) was observed at just 4 days of age (96 HPF). No embryo survived after 120 HPF for ENS at concentrations >5 mg/mL. Collectively, it shows that EPS-ENS delay hatching optimum concentrations of less than <1 mg/mL.

Figure 1. The performance of *Ganoderma applanatum* (a) EPS and (b) ENS extract at concentrations of 0.01–10 mg/mL on the survival rate of zebrafish embryos at 0–120 h. No embryos survived for both samples at concentration tested > 5.0 mg/mL after 96 h post fertilization (HPF). Symbols: *p < 0.05, **p < 0.01 and ***p < 0.001.

2.2. Performance of EPS-ENS Doses on the Zebrafish Embryos Mortality

Overall, extracts of European *G. applanatum* EPS-ENS have lethal effects that vary with dose and time. In Figure 2, at low concentrations, EPS (<3 mg/mL) and ENS (<1 mg/mL) were both able to prevent 90% of zebrafish embryos from dying. However, at high concentrations, 4 mg/mL EPS and 2 mg/mL ENS did not perform better (with low survival rate) throughout the embryo development stage, showing dead embryos post 72 HPF. Consequently, the LC50 value of zebrafish embryos exposed to EPS extract tested was
1.41 mg/mL, whereas the LC_{50} value for ENS extract tested was much lower than this at 0.87 mg/mL.

![Graph](image)

**Figure 2.** Effect of *Ganoderma applanatum* (a) EPS extract at concentrations of 0.01–10 mg/mL and (b) ENS at concentrations of 0.01–10 mg/mL on zebrafish embryos mortality rate after 120 HPF. The LC_{50} value for EPS extract was 1.41 mg/mL while LC_{50} value for EPS extract was 0.87 mg/mL. Symbols: * p < 0.05, ** p < 0.01 and *** p < 0.001.

### 2.3. Performance of EPS and ENS Doses on the Zebrafish Embryos Hatching Capability

Subsequently, different EPS-ENS concentrations of extract may affect the hatchability percentages. Figure 3 shows a trend of decreasing hatching rates with increased concentrations of the extract (>1 mg/mL) once treated into zebrafish embryos. It also depicts the hatching rate during (a) EPS treatments at 0.01–10 mg/mL and (b) ENS treatments at 0.01 to 10 mg/mL during 0 to 120 HPF period. For EPS, there was no visible changes in terms of hatching capability at concentrations less than 1 mg/mL, but the rate dropped to 35% at 48 HPF once exposed to 5 mg/mL. Zebrafish did not hatch or survive when treated with a concentration of 10 mg/mL EPS, indicating that high amounts of EPS causes strong suppression of zebrafish embryo at 24 HPF. On the other hand, less than 81% of the embryos hatched on 48 h treatment with ENS at concentrations >0.5 mg/mL; although, zebrafish larvae treated with ENS concentrations at 5 to 10 mg/mL showed the lower hatching rate (<65%) due to high mortality rate after 72 HPF.
Figure 3. Hatching rate of zebrafish embryos at 0 to 120 h of post exposure with *Ganoderma applanatum* EPS and ENS extract at concentrations of 0.01–10 mg/mL. (a) For EPS, low hatching rate (<40%) was observed at concentration 5.0 mg/mL due to high mortality rate. Meanwhile, (b) for ENS, low hatching rate (<30%) was observed at concentrations 10 mg/mL due to high mortality rate. High hatching rate was observed at concentrations >1.0 mg/mL (>80%). Symbols: * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$.

2.4. The Effects of EPS and ENS on the Heart Rate of Zebrafish Embryos

In the development of many model organisms, zebrafish heart represents the core of functional organ [27]. Based on Figure 4, both extracts of EPS and ENS at low concentrations <1 mg/mL, showed no significant difference towards the heart rate of untreated zebrafish embryo at 96 HPF. The heart rate at day 4 (96 HPF) for EPS (Figure 4a) treatment was healthily recorded at $176.44 \pm 0.77$ beats min$^{-1}$ at concentrations <1 mg/mL compared to normal average zebrafish embryonic heart rate (120–180 beats min$^{-1}$). Meanwhile, ENS (Figure 4b) treatment also gave normal heart rate ($148.44 \pm 17.75$ beats min$^{-1}$) at
concentrations <1 mg/mL. Since EPS extract at 5 and 10 mg/mL killed the zebrafish at 96 HPF, the embryonic heart rate at these concentrations were omitted. However, the embryo was barely alive when treated with 5 mg/mL of ENS (90 beats min$^{-1}$) and unrecorded at 10 mg/mL due to death. Both EPS and ENS treatments verified the previous report in which the normal heart rate of zebrafish embryo nearly mimics human condition at 120 to 180 beats min$^{-1}$ [28].

![Figure 4](image_url)

**Figure 4.** Effect of *Ganoderma applanatum* EPS and ENS extract at concentrations of 0.01–1.0 mg/mL on heart rate of zebrafish embryos at 96 HPF. For (a) EPS, no data at concentrations >5.0 mg/mL due to embryo death. Meanwhile, (b) for ENS, no data at concentrations 10.0 mg/mL recorded due to embryo death. *** p < 0.05 significantly different from the untreated group (zebrafish embryos in medium only).

2.5. Performance of EPS and ENS Doses on the Morphology of Larvae and Zebrafish Embryos Development

The performance of EPS and ENS doses were observed from 0 to 120 HPF period particularly on larvae and zebrafish embryos morphological defects. Figure 5 depicts no visible teratogenic effect of either EPS or ENS at concentrations <1 mg/mL on the embryogenesis stages at 120 h after exposing the embryos to them. Based on these data, it clearly suggested that either EPS or ENS has affected larvae and zebrafish embryos development before and after hatching.
Figure 5. Effect of EPS-ENS extracts (0.01–1 mg/mL) of European *Ganoderma applanatum* showing normal zebrafish embryogenesis at different HPF development. The inverted microscope was used to produce the images and edited using paint 3D [11]. There were 4 periods depicted: Blastula (4 HPF), Segmentation (24 HPF), Pharyngula (48 HPF), and Hatching (72 HPF). Y—yolk sac; S—somites; P—pericardium; O—ear bud; M—melanophores; G—gut; F—fin; Ch—chorion; C—chorda; Bc—blood cells; An—anus; A—eye anlage. Scale bar = 0.5 mm.

As both zebrafish embryo and larvae development were unaffected when treated with 1 mg/mL EPS and 1 mg/mL ENS, various abnormalities were observed as the concentration significantly spiked to 5 mg/mL EPS (Figure 6) and 1.31 mg/mL ENS (Figure 7). One of the most prone abnormalities was observed for ENS showing the period of coagulated embryos from 24 HPF (segmentation) to 48 HPF (pharyngula), and loss of yolk sac, resulting in unhatched embryos even after 120 HPF. Meanwhile, ENS-treated zebrafish managed to hatch at 72 HPF, however with tail malformation and broken blood cells after 120 HPF. Most of normal features were also absent such as fin, gut, and melanophores.
Figure 6. Images of zebrafish embryo and larvae development at 0 HPF, 24 HPF, 48 HPF, 72 HPF, 96 HPF and 120 HPF after treated with European <i>Ganoderma applanatum</i> at high EPS concentration of 5.0 mg/mL. Images were captured using inverted microscope at 100× (0 and 24 HPF) and 40× magnification (48–20 HPF).

Figure 7. Images of zebrafish embryo and larvae development at 0 HPF, 24 HPF, 48 HPF, 72 HPF, 96 HPF and 120 HPF after treated with European <i>Ganoderma applanatum</i> at high ENS concentration of 1.31 mg/mL. Images were captured using inverted microscope at 100× (0 and 24 HPF) and 40× magnification (48–20 HPF).
3. Discussion

In this study, both EPS and ENS extracted from bioreactor-grown European G. applanatum were analyzed for acute toxic effects in treated zebrafish embryo. EPS-ENS originates from edible mushroom species and has potential to be used as high-value product in the form of dietary fish feed supplement [29]. Recently, use of EPS-ENS (or beta-glucan) extracts has increased in interest for various applications, such as for preventing biofilms [30] and for fish-feed [10]. Beta-glucans derived from mushrooms and other sources, have also been reported as potential new therapeutic to help fight Coronavirus disease (COVID-19) in the form of potential immunotherapies [31]; to alleviate use of frontline antibiotics for combating resilient bacteria [32]; as an alternative to the use of silver nanoparticles [33]; or for other potential applications such as cosmetics [34], immune priming or boosting [12], and prevention of cell death [2]. However, study on the toxicity of these specific compounds are lacking, including use of Zebrafish testing, which would help inform product development and applications.

Using this ZFET technique, healthy zebrafish embryos, or larvae, have been used as surrogate animal model, which offers several advantages such as efficient, fast, reliable and comparable to human model [23,35]. This suits the “Zebrafish 3.0” toxicity model as the strategy share many physiological and cellular characteristics with higher vertebrates. In addition, the current ZFET assay uses 96-well plate that have a direct contact with EPS-ENS, mimicking the close contact with the demersal characteristic of zebrafish embryo. Secondly, extra-uterine and transparency can be examined, representing clear phenotypic embryonic development changes. In this study, teratogenic and embryotoxic effects evaluations are essential for EPS-ENS to determine the concentration that is safe for consumption. With booming global health industry and products from plants and fungi, claimed to have strong pharmacological responses, most of them are still dubious on the toxicological profiles.

In this study, fertilized zebrafish embryos were exposed to concentrations of G. applanatum extract, EPS (0.01–10 mg/mL) and ENS (0.01–10 mg/mL) that were shown to be non-toxic using this ZFET technique. Overall, EPS at concentrations <1 mg/mL and ENS at <1 mg/mL did not cause delay hatching towards the embryo and with 88% survival rate at 24 to 120 HPF. Additionally, there were no significant changes in both EPS and ENS at concentration <1 mg/mL on the embryo heart rate compared to the normal ones. Moreover, teratogenic effect and zebrafish embryo abnormalities can only be observed at concentrations >5 mg/mL and >1 mg/mL in EPS and ENS, respectively. The test showed that EPS has a higher LC_{50} value of 1.41 mg/mL, meaning that it is better than ENS with lower LC_{50} value (0.87 mg/mL). Even though both EPS and ENS extracts originated from G. applanatum mycelium, they may differ in terms of compound composition which originated from fruiting body and different mycelial extraction procedures [36–38]. Former research verified that similar EPS from the sister G. lucidum mycelium exhibit a broad range of bioactivities, including immunostimulant and antitumorigenic effects [39], which are higher than those of the fruiting bodies [34]. Meanwhile, ENS has given a lower LC_{50} value than EPS due to its different mycelial extraction methodology; EPS is directly extracted from the surface of fungal mycelium while ENS has undergone series of physico-chemical extractions from the internal part of dried fungal mycelium [5].

Morphological deformities, including tail malformation, could restrict the embryo’s ability to break the chorion (Ch in Figure 6) and hatch out post 5 days. Likewise, the absence of heartbeat and coagulated embryo is considered as lethal effects. The work of Dulay et al. [40] has confirmed that tail malformation in zebrafish embryo does occur when exposed to 10 mg/mL of Ganoderma sp. fruiting body extract. In addition, it depicted that the safety threshold concentration is <10 mg/mL for any Ganoderma sp. fruiting body extract [40], which is in-line with the current data described for G. applanatum EPS and ENS possessing less toxic responses.

Some medicinal mushrooms have also been studied on the effects of toxicity towards zebrafish embryos in comparison to Ganoderma species. Exposure of termite-mound mushroom Termitomyces clypeatus extract at concentrations of >0.1% reduces the zebrafish
embryos hatchability and <50% extract gave visible teratogenic effects post 48 HPF [41,42]. On the other hand, exposure of grey oyster mushroom *Pleurotus ostreatus* ethanol extract killed the zebrafish embryos using 2.5 and 5% concentrations post 12 HPF, while obstructed growth and tail malformation can be observe at 1% dose [43].

Recent studies have reported that *G. applanatum* polysaccharides are heavily used as food supplements for human species [19,44,45] to improve growth and immunity but none was tested as aquatic feed. The closest comparison were only by its popular sister *G. lucidum* at acceptable concentrations ranging from 1.0 to 1.5 g/kg on giant freshwater prawn (*Macrobrachium rosenbergii*) [46] and grass carp (*Ctenopharyngodon idella*) [47], which enhance innate immune response and development. Therefore, to gain safety concentration for both aquaculture feed and human drug, both EPS and ENS extracts from *G. applanatum* toxicity reports are essential. Henceforth, the current novel ZFET data may provide useful information for assessing the potential health risks of the EPS-ENS consortia. Still, further tests are merited to evaluate the LC$_{50}$ value of EPS-ENS extract for informing large-scale human trials and for larger animals (e.g., pig, rabbit, and adult trout), before this innovation can be deployed for commercial use.

This constitutes the first toxicology study that addresses bioreactor-cultured European *G. applanatum* (temperature climate mushroom) extracts where findings are compared to that of extracts derived from its sister *G. lucidum* (Table 1). Three studies have previously reported on the evaluation of EPS from *G. lucidum* using ZFET assay (2648 µg/mL) [11], normal prostate cell line (500 µg/mL) [48], and normal human lung cell (1000 µg/mL) [49]. The findings from this present study reports on testing and evaluation of both non-toxic mycelial EPS (1410 µg/mL) and ENS (870 µg/mL) of stirred-tank bioreactor grown *G. applanatum* samples using the zebrafish 3.0 toxicity model. Moreover, this study provided evidence to support the safe use of European *G. applanatum* bioactive polysaccharides via Zebrafish model.

### Table 1. Comparison with published non-toxicity assessment of exopolysaccharide (EPS) and endopolysaccharide (ENS) from the mushroom *Ganoderma* sp.

| Source          | Toxicological Model                          | Non-Toxic Concentrations (µg/mL) | References |
|-----------------|----------------------------------------------|----------------------------------|------------|
|                 |                                              | Exopolysaccharide (EPS)          |            |
| *G. applanatum* | In vivo—Zebrafish embryos and larvae         | 1410                             | Current study |
| BGS6Ap          |                                              | Endopolysaccharide (ENS)         |            |
| *G. lucidum*    | In vivo—Zebrafish embryos and larvae          | 2648                             | [11]        |
| QRS 5120        |                                              | NA                               |            |
| *G. lucidum*    | In vitro—normal human prostate cell line (PN2TA) | 500                              | [48]        |
| BCCM 31549      |                                              | NA                               |            |
| *G. lucidum*    | In vitro—normal human lung cell (WRL68)      | 1000                             | [49]        |

### 4. Materials and Methods

#### 4.1. European *Ganoderma Applanatum* Bioreactor Fermentation

European *G. applanatum* strain BGS6Ap was isolated by Prof. Dr. Anita Klaus from the Republic of Serbia in the wild region of Mount Kosmaj at temperate environment (18 °C–24 °C), coordinate of 44°27′57″ N, 20°33′52″ E, and maintained at 4 °C on Malt Extract Agar (MEA) slants prior to fermentation setup. The bioreactor fermentation of *G. applanatum* consists of double-seed culture stages. The seed culture medium condition was previously optimized for! Ganoderma sp. liquid batch fermentation at fixed metrics (g/L): Yeast extract 1, Glucose 30, KH$_2$PO$_4$ 0.5, MgSO$_4$ 0.5, and NH$_4$Cl 4 [50]. The fungus was cultivated for ten days at pre-optimized condition of 25 °C, pH 6, 10 g/L of glucose and 150 rpm in a 5-L stirred-tank (STR- Labfors, Infors H-T, Basel, Switzerland) bioreactor [51] to produce fungal biomass.
4.2. G. applanatum EPS-ENS Preparations

The fungal biomass from the harvested G. applanatum culture was subjected to Buchner funnel filtration, followed by triple washing with distilled water. To obtain EPS, the filtrate was precipitated by the addition of four volumes of 99% (v/v) cold-ethanol-shock treatment and left overnight at 4 °C. After 24 h, crude EPS was formed naturally by agglomeration, and centrifuged at 10,000 rpm for 20 min. Meanwhile, to obtain ENS, the initial washed-fungal biomass was dried in a dryer until it powdered. The dried biomass was mixed with 1 g:20 mL distilled water, then subjected to heat-extraction (24 °C for 30 min) [52]. The resulting crude ENS was precipitated using the similar procedure of crude EPS. Finally, both EPS and ENS crude extracts were slow-dried to constant weight prior to toxicity studies. Stock powder of dried EPS-ENS was diluted in embryo medium (Danio-SprintM solution) producing working solutions (10 mg/mL). The mixture was diluted in 2-fold serial dilutions obtaining six concentrations ranging from 0.01–5 mg/mL in a 96-well microplate (200 µL). Embryos as in embryo medium were assigned as standard control (untreated).

4.3. Zebrafish Maintenance and Breeding

The use of zebrafish was approved under the by the Institutional Animal Care and Use Committee (IACUC), Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia. Briefly, zebrafish of both sexes were placed into a breeding tank on the day the breeding tank was prepared. Following the first day, embryos were collected, washed, and then incubated in Danio-SprintM solution. Dead and coagulated embryos were discarded in an attempt to find healthy embryos [11].

4.4. Zebrafish Embryo Toxicity (ZFET) Assay

The standard of Organization for Economic Cooperation and Development (OECD) standard was used in the ZFET assay [53]. Initially, one zebrafish embryo per well system at 0 HPF were subjected to diluted EPS-ENS samples (200 µL) in 96-well microplates (Corning® 96 Well Clear Polystyrene Microplate, Corning, NY, USA) at seven different concentrations ranging from 0.01–10 mg/mL. The EPS-ENS and untreated samples were tested with a total of 24 replicate of embryos per exposure group slight above minimum standard [54,55]. Successful treated embryos were incubated at room temperature (25–28 °C) for 5 days. The cumulative mortality and developmental malformations of embryos and larvae were observed and determined every 24 h from 0–120 HPF as previously suggested by Parenti et al., [56]. The results indicate that mortality, hatching rate, heart rate, morphological malformation or teratogenic defects were observed using THUNDER Imager 3D Live Cell & 3D Cell Culture & 3D Assay, Leica Microsystems GmbH, Wetzlar, Germany. Heartbeat (1 min) and lethal endpoints (no heartbeat and clear coagulation) were assessed as according to Taufek et al., [11]. Anomalous development includes yolk sac oedema, curved body, non-hatched, bent tail and pericardial oedema. The principle of toxicity (LC<sub>50</sub>) values for EPS-ENS derivative >1 mg/mL are considered relatively harmless, 0.1–1 mg/mL are considered practically non-toxic, 0.01–0.1 mg/mL are considered slightly toxic, 0.001–0.01 mg/mL are considered moderately toxic, 0.0001–0.001 mg/mL are considered highly toxic and <0.0001 mg/mL are considered super toxic. Video S1: EPS-ENS Untreated vs. 0.01, 0.5 and 1 mg/mL treatments was supplied as supplementary data.

4.5. Statistical Analysis

ZFET response graphs and the lethal concentration at 50% (LC<sub>50</sub>) of treated samples toward zebrafish embryos were produced by using GraphPad Prism version 9.0 (GraphPad Software, Inc., 2365 Northside Dr. Suite 560, San Diego, CA, USA). Heart rate response was presented as mean ± standard error of mean (S.E.M) from three different animals. One-way analysis of variance (ANOVA) was used to carry out the significant differences with a post hoc test via Dunnett’s Multiple Comparison. The significant difference was
considered at * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$ between the means of treated group as compared to embryos in embryo medium.

5. Conclusions

In conclusion, this represents the first study to report on the use of zebrafish embryo toxicity (ZFET) assay on bioreactor-grown European medicinal mushroom *G. applanatum* EPS and ENS extracts. EPS (LC$_{50}$: 1.41 mg/mL) was harmless while ENS (LC$_{50}$: 0.87 mg/mL) are practically non-toxic. The ZFET assay offers a fast, affordable, robust, and efficient early development approach to evaluating extracts from medicinal fungi for future use in aquaculture [57]. Findings will inform and guide future “foodomics” research spanning molecular toxicology and linked proteomics and metabolomics as it relates to targeting specific transcripts for biosensor development that will support end-to-end monitoring of value chain, including using of machine learning for mitigating food waste and improving “circularity” for the food sector. Specifically, this study provides new knowledge that will inform efficacy for future immune-priming and disease mitigation innovation for global food security.

Supplementary Materials: The following are available online at https://www.mdpi.com/1422-0067/22/4/1675/s1, Video S1: EPS-ENS Untreated vs. 0.01, 0.5 and 1 mg/mL treatments.

Author Contributions: Conceptualization, W.A.A.Q.I.W.-M. and N.R.; methodology, W.A.A.Q.I.W.-M. and N.R.; software, W.A.A.Q.I.W.-M. and N.R.; validation, Z.I. and A.A.J.; formal analysis, W.A.A.Q.I.W.-M.; investigation, W.A.A.Q.I.W.-M.; resources, N.R.; data curation, W.A.A.Q.I.W.-M. and N.R.; writing—original draft preparation, W.A.A.Q.I.W.-M.; writing—review and editing, Z.I. and A.A.J.; visualization, W.A.A.Q.I.W.-M.; supervision, W.A.A.Q.I.W.-M.; project administration, W.A.A.Q.I.W.-M. and N.R.; funding acquisition, W.A.A.Q.I.W.-M. and N.R. All authors have read and agreed to the published version of the manuscript.

Funding: We want to thank Universiti Malaya under the Research University Grant- Faculty Program GPF084A-2020 and MOHE- Top 100 (IIRG)-IIS: IIRG003A-2020 IIS awarded to Wan-Mohtar. The work was also funded by H2020 MSCA RISE ICHTHYS project [number 872217/19] awarded to Neil Rowan.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Organization for Economic Cooperation and Development (OECD) No. 236; Fish Embryo Acute Toxicity (FET) Test (OECD, 2013) under compliance of IACUC UPM.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy.

Acknowledgments: We would like to thank Anita Klaus for European *G. applanatum* strain BGS6Ap isolated by from the Republic of Serbia in the wild region of Mount Kosmaj. Sincere gratitude to Danio Assay Team, Department of Biochemistry, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang, Selangor for technical support.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Venturella, G.; Ferraro, V.; Cirilincione, F.; Gargano, M.L. Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials. *Int. J. Mol. Sci.* 2021, 22, 634. [CrossRef]
2. Liang, Z.; Yuan, Z.; Guo, J.; Wu, J.; Yi, J.; Deng, J.; Shan, Y. Ganoderma lucidum polysaccharides prevent palmitic acid-evoked apoptosis and autophagy in intestinal porcine epithelial cell line via restoration of mitochondrial function and regulation of MAPK and AMPK/Akt/mTOR signaling pathway. *Int. J. Mol. Sci.* 2019, 20, 478. [CrossRef]
3. Klaus, A.; Wan-Mohtar, W.A.A.Q.I.; Nikolić, B.; Cvetković, S.; Vunduk, J. Pink oyster mushroom *Pleurotus flabellatus* mycelium produced by an airlift bioreactor—the evidence of potent in vitro biological activities. *World J. Microbiol. Biotechnol.* 2021, 37, 1–14.
4. Wan-Mohtar, W.A.A.Q.I.; Halim-Lim, S.A.; Kamarudin, N.Z.; Rukayadi, Y.; Abd Rahim, M.H.; Jamaludin, A.A.; Ilham, Z. Fruiting-body-base flour from an Oyster mushroom waste in the development of antioxidative chicken patty. *J. Food Sci.* 2020, 85, 3124–3133. [CrossRef]
5. Abdullah, N.R.; Sharif, F.; Azizan, N.H.; Hafidz, I.F.M.; Supramani, S.; Usuldin, S.R.A.; Ahmad, R.; Wan-Mohtar, W.A.A.Q.I. Pellet diameter of Ganoderma lucidum in a repeated-batch fermentation for the trio total production of biomass-exopolysaccharide-endopoly saccharide and its anti-oral cancer beta-glucan response. *AIMS Microbiol.* 2020, 6, 379. [CrossRef] [PubMed]

6. Rota, E.; De Luca, F.; Di Iorio, C.; Ratto, D.; Siciliani, S.; Ferrari, B.; Cobelli, F.; Borsci, G.; Priori, E.C.; Chinosi, S. Novel Medicinal Mushroom Blend as a Promising Supplement in Integrative Oncology: A Multi-Tiered Study using 4T1 Triple-Negative Mouse Breast Cancer Model. *Int. J. Mol. Sci.* 2020, 21, 3479. [CrossRef] [PubMed]

7. O’Neill, E.A.; Rowan, N.J.; Fogarty, A.M. Novel use of the alga Pseudokirchneriella subcapitata, as an early-warning indicator to identify climate change ambiguity in aquatic environments using freshwaterfinfish farming as a case study. *Sci. Total Environ.* 2019, 692, 209–218. [CrossRef]

8. Tahar, A.; Kennedy, A.; Fitzgerald, R.D.; Clifford, E.; Rowan, N. Full water quality monitoring of a traditional flow-through rainbow trout farm. *Fishes* 2018, 3, 28. [CrossRef]

9. O’Neill, E.A.; Stejskal, V.; Clifford, E.; Rowan, N.J. Novel use of peatlands as future locations for the sustainable intensification of freshwater aquaculture production—A case study from the Republic of Ireland. *Sci. Total Environ.* 2020, 706, 136044. [CrossRef]

10. Wang-Mohtar, W.A.A.Q.I.; Taufek, N.M.; Yerima, G.; Rahman, J.; Thiran, J.P.; Subramaniam, K.; Sabaratnam, V. Effect of bioreactor-grown biomass from Ganoderma lucidum lucidum mycelium on growth performance and physiological response of red hybrid tilapia (*Oreochromis* sp.) for sustainable aquaculture. *Org. Agric.* 2020. [CrossRef]

11. Taufek, N.M.; Harith, H.H.; Abd Rahim, M.H.; Ilham, Z.; Rowan, N.; Wan-Mohtar, W.A.A.Q.I. Performance of mycelial biomass and exopolysaccharide from Malaysian Ganoderma lucidum for the fungivore red hybrid Tilapia (*Oreochromis* sp.) in Zebrafish embryo. *Aquac. Rep.* 2020, 17, 100322. [CrossRef]

12. Murphy, E.J.; Rezoagli, E.; Major, I.; Rowan, N.J.; Laffey, J.G. β-glucan metabolic and immunomodulatory properties and potential for clinical application. *J. Fungi* 2020, 6, 356. [CrossRef]

13. Supramani, S.; Jailani, N.; Ramarao, K.; Zain, N.A.M.; Klaus, A.; Ahmad, R.; Wan-Mohtar, W.A.A.Q.I. Pellet diameter and morphology of European Ganoderma pfeifferi in a repeated-batch fermentation for exopolysaccharide production. *Biocatal. Agric. Biotechnol.* 2019, 19, 101118. [CrossRef]

14. Hassan, N.A.; Supramani, S.; Sohdein, M.N.A.; Usuldin, S.R.A.; Klaus, A.; Ilham, Z.; Chen, W.-H.; Wan-Mohtar, W.A.A.Q.I. Efficient biomass-exopolysaccharide production from an identified wild-Serbian Ganoderma lucidum strain BF44A1 mycelium in a controlled submerged fermentation. *Biocatal. Agric. Biotechnol.* 2019, 21, 101305. [CrossRef]

15. Deborah Paripuranam, T.; Divya, V.; Ulaganathan, P.; Balamurugan, V.; Umamaheswari, S. Replacing fish meal with earthworm pellets diameter and morphology of *Asparagopsis taxiformis* mushroom extract on the immune response of rainbow trout, Oncorhynchus mykiss, and disease resistance against *Lactococcus garvieae* of rainbow trout. *Fishes* 2018, 3, 28. [CrossRef]

16. Liang, D.; Yong, T.; Chen, S.; Xie, Y.; Chen, D.; Zhou, X.; Li, D.; Li, M.; Su, L.; Zuo, D. Hypouricemic effect of 2, 5-dihydroxyacetophenone, a computational screened bioactive compound from Ganoderma applanatum, on hyperuricemic mice. *Int. J. Mol. Sci.* 2018, 19, 1394. [CrossRef] [PubMed]

17. Tangan, L.; Zhu, Z.-F.; Cao, L.-P.; Shen, M.; Gao, Y.; Tu, C.-J.; Zhang, Z.-H.; Shan, W.-G. Thermosensitive gel of polysaccharide from *Ganoderma applanatum* combined with paclitaxel for mice with 4T1 breast cancer. *Zhongguo Zhong Yao Za Zhi Zhongguo Zhongyao Zazhi China J. Clin. Mater. Med.* 2020, 45, 2533–2539. [CrossRef]

18. Hanyu, X.; Lanyue, L.; Miao, D.; Wentao, F.; Cangran, C.; Hui, S. Effect of Ganoderma applanatum polysaccharides on MAPK/ERK pathway affecting autophagy in breast cancer MCF-7 cells. *Int. J. Biol. Macromol.* 2020, 146, 353–362. [CrossRef]

19. Rahmann, G.; Grimm, D.; Kuenz, A.; Hessel, E. Combining land-based organic and landless food production: A concept for a circular and sustainable food chain for Africa in 2100. *Org. Agric.* 2020, 10, 9–21. [CrossRef]

20. Marino, F.; Di Caro, G.; Gugliandolo, C.; Spano, A.; Faggio, C.; Genovese, G.; Morabito, M.; Russo, A.; Barreca, D.; Fazio, F. Preliminary study on the in vitro and in vivo effects of *Asparagopsis taxiformis* bioactive phycoderivates on teleosts. *Front. Physiol.* 2016, 7, 459. [CrossRef] [PubMed]

21. Lo Cascio, P.; Calabrò, C.; Bertuccio, C.; Iaria, C.; Marino, F.; Denaro, M.G. Immunohistochemical characterization of PepT1 and ghrelin in gastrointestinal tract of zebrafish: Effects of Spirulina vegetarian diet on the neuroendocrine system cells after alimentary stress. *Front. Physiol.* 2018, 9, 614. [CrossRef] [PubMed]

22. Ghilardi, A.; Zammuto, V.; Minicante, S.A.; Manghisi, A.; Cigala, R.M. Potential antibacterial activity of marine macroalgae against pathogens relevant for aquaculture and human health. *J. Pure Appl. Microbiol.* 2017, 11, 1695–1706. [CrossRef]

23. Zhang, X.-H.; Fan, H.; He, X.; Austin, B. Vibrio harveyi: A serious pathogen of fish and invertebrates in mariculture. *Mar. Life Sci. Technol.* 2020, 2, 1–15. [CrossRef] [PubMed]
27. Bakkers, J. Zebrafish as a model to study cardiac development and human cardiac disease. *Cardiovasc. Res.* 2011, 91, 279–288. [CrossRef]

28. Baker, K.; Warren, K.S.; Yellen, G.; Fishman, M.C. Defective “pacemaker” current (Ih) in a zebrafish mutant with a slow heart rate. *Proc. Natl. Acad. Sci. USA* 1997, 94, 4534–4539. [CrossRef]

29. Kozarski, M.S.; Klaus, A.S.; Vunduk, J.D.; Jakovljević, D.M.; Jadranin, M.B.; Nikšić, M.P. Health impact of commercially cultivated mushroom Agaricus bitorus and wild-growing mushroom *Ganoderma resinaceum*—a comparative overview. *J. Serb. Chem. Soc.* 2020, 85, 721–735. [CrossRef]

30. Vunduk, J.; Wan- Mohtar, W.A.Q.I.; Mohamad, S.A.; Abd Halim, N.H.; Dzomir, A.Z.M.; Žižak, Ž.; Klaus, A. Polysaccharides of *Pleurotus flabellatus* strain Mynuk produced by submerged fermentation as a promising novel tool for adhesion and biofilm formation of foodborne pathogens. *LWT* 2019, 112, 108221. [CrossRef]

31. Murphy, E.J.; Masterson, C.; Rezoagli, E.; O’Toole, D.; Major, I.; Stack, G.D.; Lynch, M.; Laffey, J.G.; Rowan, N.J. β-Glucan extracts from the same edible shitake mushroom *Lentinus edodes* produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects—Implications for coronavirus disease (COVID-19) immunotherapies. *Sci. Total Environ.* 2020, 732, 139330. [CrossRef]

32. Masterson, C.H.; Murphy, E.J.; Gonzalez, H.; Major, I.; McCarthy, S.; O’Toole, D.; Laffey, J.G.; Rowan, N.J. Purified β-glucans from the Shiitake mushroom ameliorates antioxidant-resistant Klebsiella pneumoniae-induced pulmonary sepsis. *Lett. Appl. Microbiol.* 2020, 71, 405–412. [CrossRef] [PubMed]

33. Klaus, A.; Petrovic, P.; Vunduk, J.; Pavlovic, V.; Van Griensven, L.J.L.D. The antimicrobial activities of silver nanoparticles synthesized from medicinal mushrooms. *Int. J. Med. Mushrooms* 2020, 22, 869–883. [CrossRef] [PubMed]

34. Kozarski, M.; Klaus, A.; Jakovljević, D.; Todorović, N.; Wan- Mohtar, W.A.Q.I.; Nikšić, M. *Ganoderma lucidum* as a cosmeceutical: Antiradical potential and inhibitory effect on hyperpigmentation and skin extracellular matrix degradation enzymes. *Arch. Biol. Sci.* 2019, 71, 253–264. [CrossRef]

35. Della Torre, C.; Maggioni, D.; Ghilardi, A.; Parolini, M.; Santo, N.; Landi, C.; Madaschi, L.; Magni, S.; Tasselli, S.; Ascagni, M. The interactions of fullerene C60 and Benzo (α) pyrene influence their bioavailability and toxicity to zebrafish embryos. *Environ. Pollut.* 2018, 241, 999–1008. [CrossRef] [PubMed]

36. Zhao, L.Y.; Dong, Y.H.; Chen, G.T.; Hu, Q.H. Extraction, purification, characterization and antitumor activity of polysaccharides from *Ganoderma lucidum*. *Carbohyd. Polym.* 2010, 80, 783–789. [CrossRef]

37. Ma, Y.; He, H.; Wu, J.; Wang, C.; Chao, K.; Huang, Q. Assessment of Polysaccharides from Mycelia of genus *Ganoderma* by Mid-Infrared and Near-Infrared Spectroscopy. *Sci. Rep.* 2018, 8, 10. [CrossRef] [PubMed]

38. Huang, Y.; Li, N.; Wan, J.B.; Zhang, D.; Yan, C. Structural characterization and antioxidant activity of a novel heteropolysaccharide from the submerged fermentation mycelia of *Ganoderma capense*. *Carbohydr. Polym.* 2015, 134, 752–760. [CrossRef]

39. Ahmadifar, E.; Dawood, M.A.; Moghadam, M.S.; Sheikhzadeh, N.; Hoseinifar, S.H.; Musthafa, M.S. Modulation of immune parameters and antioxidant defense in zebrafish (Danio rerio) using dietary apple cider vinegar. *Aquaculture* 2019, 513, 734412. [CrossRef] [PubMed]

40. Dulay, R.M.R.; Kalaw, S.P.; Reyes, R.G.; Alfonso, N.F.; Eguchi, F. Teratogenic and Toxic Effects of Lingzhi or Reishi Medicinal Mushrooms, *Ganoderma lucidum*, on the growth characteristics of human cell lines. *Int. J. Mol. Sci.* 2021, 22, 1675. [CrossRef]

41. De Castro, M.E.G.; Dulay, R.M.R.; Enriquez, M. Toxic and Teratogenic Effects of Medicinal and Culinary Mushroom, *Tremellomyces glypeptus*, Collected from the Termite Mound in Mt. Makiling Forest Reserve, Los Baños, Laguna, Philippines on Developing Embryos Of Zebrafish (*Danio rerio*). *Lett. Appl. Microbiol.* 2016, 6, 237–242. [CrossRef] [PubMed]

42. Wu, X.; Hao, Q.; Teame, T.; Ding, Q.; Liu, H.; Ran, C.; Yang, Y.; Xia, L.; Wei, S.; Zhou, Z. Gut microbiota induced by dietary GWF® contributes to growth promotion, immune regulation and disease resistance in hybrid sturgeon (Acipenserbaerii x Acipensershrenckii): Insights from a germ-free zebrafish model. *Aquaculture* 2020, 520, 734966. [CrossRef]

43. De Castro, M.; Dulay, R.M.R. Toxic and teratogenic effects of *Lentinus sajor-caju* and *Pleurotus ostreatus* ethanolic extracts in *Danio rerio* embryo model. *Int. J. Biol. Pharm. Allied Sci.* 2015, 4, 2261–2269. [CrossRef]

44. Gao, Z.; Yuan, F.; Li, H.; Feng, Y.; Zhang, Y.; Zhang, C.; Zhang, J.; Song, Z.; Jia, L. The ameliorations of *Ganoderma applanatum* residue polysaccharides against CIC induced liver injury. *Int. J. Biol. Macromol.* 2019, 137, 1130–1140. [CrossRef]

45. Zhen, D.; Su, L.; Miao, Y.; Zhao, F.; Ren, G.; Mahfuz, S.; Song, H. Purification, partial characterization and inducing tumor cell apoptosis activity of a polysaccharide from *Ganoderma applanatum*. *Int. J. Biol. Macromol.* 2018, 115, 10–17. [CrossRef]

46. Mohan, K.; Muralisankar, T.; Uthayakumar, V.; Chandirasekar, R.; Rajan, D.K. Dietary *Ganoderma lucidum* polysaccharides to enhance the growth, immune response and disease resistance of freshwater prawn *Macrobrachium rosenbergii*. *Aquac. Res.* 2019, 14, 100203. [CrossRef]

47. Chithra, E.; Padmanaban, A.; Mohan, K. Potential use of *Ganoderma lucidum* polysaccharides as a feed supplement in diets on survival and growth performance of the grass carp, *Ctenopharyngodon idella*. *Int. J. Fish. Aquac. Stud.* 2016, 4, 328–333. [CrossRef]

48. Wan-Mohtar, W.A.Q.I.; Young, L.; Abbott, G.M.; Clements, C.; Harvey, L.M.; McNeil, B. Antimicrobial properties and cytotoxicity of sulfated (1,3)-beta-D-glucan from the mycelium of the mushroom *Ganoderma lucidum*. *J Microbiol. Biotechnol.* 2016, 26, 999–1010. [CrossRef] [PubMed]

49. Chung, W.T.; Lee, S.H.; Dai Kim, J.; Park, Y.S.; Hwang, B.; Lee, S.Y.; Lee, H.Y. Effect of mycelial culture broth of *Ganoderma lucidum* on the growth characteristics of human cell lines. *J. Biosci. Bioeng.* 2001, 92, 550–555. [CrossRef]
50. Supramani, S.; Rahayu Ahmad, Z.I.; Annuar, M.S.M.; Klaus, A.; Wan-Mohtar, W.A.A.Q.I. Optimisation of biomass, exopolysaccharide and intracellular polysaccharide production from the mycelium of an identified *Ganoderma lucidum* strain QRS 5120 using response surface methodology. *AIMS Microbiol.* 2019, 5, 19. [CrossRef] [PubMed]

51. Usuldin, S.R.A.; Mahmud, N.; Ilham, Z.; Ikram, N.K.K.; Ahmad, R.; Wan-Mohtar, W.A.A.Q.I. In-depth spectral characterization of antioxidative (1, 3)-β-D-glucan from the mycelium of an identified tiger milk mushroom *Lignosus rhinocerus* strain ABI in a stirred-tank bioreactor. *Biocatal. Agric. Biotechnol.* 2020, 23, 101455. [CrossRef]

52. Nik Ubaidillah, N.H.; Abdullah, N.; Sabaratnam, V. Isolation of the intracellular and extracellular polysaccharides of *Ganoderma neojaponicum* (Imazeki) and characterization of their immunomodulatory properties. *Electron. J. Biotechnol.* 2015, 18, 188–195. [CrossRef]

53. OECD. Test No. 236: *Fish Embryo Acute Toxicity (FET) Test*; OECD Publishing: Paris, France, 2013.

54. Aspatwar, A.; Hammaren, M.M.; Parikka, M.; Parkkila, S. Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos. *J. Vis. Exp.* 2019. [CrossRef] [PubMed]

55. Gourmelon, A.; Delrue, N. Validation in support of internationally harmonised OECD test guidelines for assessing the safety of chemicals. *Valid. Altern. Methods Toxic. Test.* 2016, 856, 9–32.

56. Parenti, C.C.; Ghilardi, A.; Della Torre, C.; Magni, S.; Del Giacco, L.; Binelli, A. Evaluation of the infiltration of polystyrene nanobeads in zebrafish embryo tissues after short-term exposure and the related biochemical and behavioural effects. *Environ. Pollut.* 2019, 254, 112947. [CrossRef]

57. Rowan, N.J.; Galanakis, C.M. Unlocking challenges and opportunities presented by COVID-19 pandemic for cross-cutting disruption in agri-food and green deal innovations: Quo Vadis? *Sci. Total Environ.* 2020, 748, 141362. [CrossRef]